Cowen and Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Cowen and Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,000	Closed	-$10K	–	758
2022 Q1	$10K	Hold	15,000	–	–	﹤0.01%	502
2021 Q4	$143K	Buy	+15,000	New	+$2.92M	0.01%	333
2021 Q2	–	Sell	-5,200	Closed	-$189K	–	706
2021 Q1	$189K	Sell	5,200 -2,300	-31%	-$505K	0.01%	277
2020 Q4	$118K	Buy	+7,500	New	+$1.72M	0.01%	210

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cowen and Company's VRTX Position: Q2 2021 in Review

Cowen and Company sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 5,773 shares — an estimated $1.24M sold.

Cowen and Company first reported a position in VRTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.24M in Q1 2021. 977 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Cowen and Company reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cowen and Company sold 5,773 Vertex Pharmaceuticals shares in Q2 2021, an estimated $1.24M.
Cowen and Company first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Cowen and Company's Vertex Pharmaceuticals position peaked at $1.24M in Q1 2021.
977 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.